oxazoles has been researched along with Parkinson Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auno, S; Cui, H; Eteläinen, TS; Jäntti, M; Julku, UH; Kilpeläinen, TP; Leino, TO; Myöhänen, TT; Norrbacka, S; Pätsi, HT; Sipari, N; Svarcbahs, R; Wallén, EAA | 1 |
| Cordaro, M; Crupi, R; Cuzzocrea, S; D'Amico, R; Di Paola, R; Gugliandolo, E; Impellizzeri, D; Peritore, AF; Siracusa, R | 1 |
| Choo, H; Choo, IH; Jo, S; Keum, G; Kim, J; Kim, T; Lee, CJ; Lee, J; Lim, EJ; Min, SJ; Moon, B; Nam, G; Park, HR; Park, KD; Yeom, M | 1 |
| Eisenstein, M | 1 |
| Dostert, P; Strolin Benedetti, M | 1 |
1 review(s) available for oxazoles and Parkinson Disease
| Article | Year |
|---|---|
Overview of the present state of MAO inhibitors.
Topics: Animals; Benzamides; Humans; Hydrazines; Isoquinolines; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Parkinson Disease; Phenethylamines; Piperidines; Selegiline; Structure-Activity Relationship | 1987 |
4 other study(ies) available for oxazoles and Parkinson Disease
| Article | Year |
|---|---|
Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Humans; Ligands; Mice; Mice, Transgenic; Oxazoles; Parkinson Disease; Prolyl Oligopeptidases; Serine Endopeptidases | 2023 |
2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Behavior, Animal; Cyclooxygenase 2; Cytokines; Disease Models, Animal; DNA Damage; Dopamine Plasma Membrane Transport Proteins; Inflammation; Mice, Inbred C57BL; Microglia; NF-E2-Related Factor 2; Nitric Oxide Synthase Type II; Nitrosative Stress; Oxazoles; Oxidative Stress; Parkinson Disease; Poly Adenosine Diphosphate Ribose; Transcription Factor RelA; Tyrosine; Tyrosine 3-Monooxygenase | 2018 |
Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Topics: Binding Sites; Catalytic Domain; Dopamine; Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxazoles; Parkinson Disease; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2013 |
Molecular biology: Remove, reuse, recycle.
Topics: Aging; Alzheimer Disease; Autophagy; Biomedical Research; Caloric Restriction; HIV; Humans; Longevity; Neoplasms; Oxazoles; Parkinson Disease; Phagosomes; Rilmenidine | 2014 |